Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Christine Bestvina and Aditya Juloori.

 
Connection Strength
 
 
 
1.074
 
  1. Korpics MC, Katipally RR, Partouche J, Cutright D, Pointer KB, Bestvina CM, Luke JJ, Pitroda SP, Dignam JJ, Chmura SJ, Juloori A. Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiotherapy and Immunotherapy. Int J Radiat Oncol Biol Phys. 2022 Jun 23.
    View in: PubMed
    Score: 0.248
  2. Korpics MC, Katipally RR, Partouche J, Cutright D, Pointer KB, Bestvina CM, Luke J, Pitroda SP, Chmura SJ, Juloori A. Prospective Evaluation of Stereotactic Body Radiotherapy and Immunotherapy for Mediastinal and Hilar Lymph Node Metastases. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):S10.
    View in: PubMed
    Score: 0.237
  3. Katipally RR, Korpics MC, Partouche J, Cutright D, Pointer KB, Bestvina CM, Luke JJ, Pitroda SP, Chmura SJ, Juloori A. Stereotactic Body Radiation Therapy and Immunotherapy in Abdominal and Pelvic Lymph Node Metastases. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):S58.
    View in: PubMed
    Score: 0.237
  4. Bestvina CM, Pointer KB, Karrison T, Al-Hallaq H, Hoffman PC, Jelinek MJ, Juloori A, Melotek JM, Murgu S, Partouche J, Vokes EE, Weichselbaum RR, Pitroda SP, Patel JD, Chmura SJ. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140.
    View in: PubMed
    Score: 0.234
  5. Pointer KB, Katipally RR, Bestvina CM, Juloori A, Partouche J, Patel JD, Pitroda SP, Vokes EE, Weichselbaum RR, Chmura SJ. Evaluation of Initial Metastatic Tumor Location and Radiation Response to Determine Outcomes in Patients Who Received Combination Stereotactic Body Radiotherapy and Immunotherapy for NSCLC. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):e449.
    View in: PubMed
    Score: 0.059
  6. Gutiontov SI, Turchan WT, Spurr LF, Rouhani SJ, Chervin CS, Steinhardt G, Lager AM, Wanjari P, Malik R, Connell PP, Chmura SJ, Juloori A, Hoffman PC, Ferguson MK, Donington JS, Patel JD, Vokes EE, Weichselbaum RR, Bestvina CM, Segal JP, Pitroda SP. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
    View in: PubMed
    Score: 0.059
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.